摘要
目的:评价DC+CIK联合常规化疗治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法:选择70例晚期NSCLC患者进行研究,采用DC+CIK与常规化疗间隔进行的方案(生物治疗联合化疗组),对其进行生存分析;同时,对生物治疗联合化疗组、单纯常规化疗组同期配对NSCLC患者各61例,比较生物治疗联合化疗组与常规化疗对照组患者的生存率。结果:生物治疗联合常规化疗组患者预期1、2、3年生存率分别为59.6%、29.6%、21.80。生物治疗联合化疗组和单纯常规化疗组比较1年生存率分别为57.2%和37.3%,2年生存率分别为27.0%和10.1%(P<0.05)。结论:临床研究证实了DC+CIK联合常规化疗能够延长晚期NSCLC患者的生存期,提高患者的生存率和生活质量。
Objective: To evaluate the clinical effects of administering dendritic cells (DC) and cytokine induced killer cells (ClK) combined with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Methods: In the present clinical study, 70 advanced NSCLC patients received DC and CIK combined with chemotherapy at a given interval (biotherapy + chemotherapy group). The clinical therapeutic effect was observed and the survival rate was determined. A total of 61 NSCLC patients were selected for analysis in the chemotherapy group, and the survival rates were compared between the two groups. Results: For advanced NSCLC patients who received biotherapy combined with chemotherapy, the 1-, 2- and 3-year survival rates were 59.6%, 29.6%, and 21.8%, respectively. The 1-year survival rate in the biotherapy + chemotherapy group and the chemotherapy group was 57.2% and 37.3%, respectively. The 2-year survival rate was 27.0% and 10.1%, respectively (P〈0.05). Conclusion: Administration of DC and CIK combined with chemotherapy can prolong survival time in NSCLC patients and improve their quality of life.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2009年第17期969-971,979,共4页
Chinese Journal of Clinical Oncology
基金
天津市科技创新专项基金资助(编号:06FZZDSF01500)